Latest

psychopharmacology

·June 30, 2026·11 min read

Creatine Shows Mixed Results in Treating Depression

A new study reveals a split decision on using creatine to treat depression. While combining creatine with standard therapy or antidepressants significantly accelerated remission in adult women, it failed in adolescent, treatment-resistant, and bipolar cohorts, even triggering mania in some bipolar patients.

Featured Neuroscience

·June 16, 2026·9 min read

Pairing Psilocybin With Stillness Could Permanently Rewire the Brain

Researchers aim to discover if mindfulness practices can provide the cognitive scaffolding necessary to sustain the intense neuroplastic states and narrative deconstruction induced by psilocybin therapy.

This shows a brain made of gut bacteria.

Featured Neuroscience Psychology

·June 10, 2026·9 min read

GLP-1 Drugs Reduce Depression, Boost Stress-Calming Gut Bacteria

The GLP-1 agonist liraglutide treats depressive symptoms via a novel microbial pathway.

Featured Neuroscience Psychology

·June 8, 2026·8 min read

SSRIs Push Serotonin Neurons in Opposite Directions

A new study maps the distinct gene-expression changes induced by fluoxetine inside the brain's primary serotonin hub, the Dorsal Raphe Nucleus.

Featured Neuroscience Psychology

·June 3, 2026·8 min read

Are Long-Term Antidepressant Benefits Overstated?

A new study reveals a lack of robust evidence proving that antidepressants prevent relapse beyond 12 months.

This shows a depressed person and a pill bottle.

Featured Neuroscience Psychology

·May 20, 2026·12 min read

Arthritis Drug Rescues Hard-to-Treat Depression

The anti-inflammatory drug tocilizumab can successfully induce remission in patients struggling with treatment-resistant depression.

Featured Neuroscience Psychology

·May 19, 2026·16 min read

Buprenorphin and Ketamine Combo Provide Anti-Suicidal Effect

A sequential combination of a single ketamine infusion followed by four weeks of low-dose daily buprenorphine successfully extends the antisuicidal window of ketamine from one fleeting week to over a month.

Featured Neuroscience Psychology

·May 15, 2026·10 min read

Single Psilocybin Dose Sparks Rapid Depression Remission

Can a single dose of psilocybin replace daily antidepressants? A new randomized clinical trial shows that a 25 mg dose of the psychedelic compound delivers rapid, clinically meaningful symptom reductions for common depression in just 48 hours.

This shows a woman with a digital contact lense on her eye.

Featured Neuroscience Psychology Visual Neuroscience

·May 14, 2026·6 min read

Brain-Stimulating Contact Lenses Match Prozac in Depression Study

Researchers have created transparent, flexible contact lenses that treat depression using "temporal interference" electrical stimulation. In a landmark study, the lenses restored brain connectivity and boosted serotonin by 47%, matching the performance of leading antidepressants.

Featured Neuroscience Psychology

·May 7, 2026·9 min read

Psilocybin Rebuilds the Brain’s Physical Wiring

New research from UCSF shows that a single high dose of the psychedelic compound creates lasting anatomical changes in brain tracts and "loosens" rigid thought patterns, leading to significant improvements in psychological insight and well-being that persist for over a month.

This shows a person's head and mushrooms.

Featured Neuroscience Open Neuroscience Articles Psychology

·May 7, 2026·8 min read

Psilocybin Dampens Aggression and Attack Behaviors

New research shows that low doses of the psychoactive compound can reduce high-energy aggressive behaviors in mangrove rivulus fish while keeping social communication intact, offering a new vertebrate model for studying the drug's impact on social conflict.

Featured Neuroscience Psychology

·May 1, 2026·11 min read

How Scientists Cracked the Ketamine Code for Depression

By "reverse engineering" ketamine, Weill Cornell investigators have identified a specific opioid receptor pathway and a unique receptor "cross-talk" that drives rapid antidepressant effects.